Heron Therapeutics Files 8-K on Shareholder Votes & Financials

TL;DR

HERON THERAPEUTICS (HRTX) filed an 8-K today covering shareholder votes and financials.

AI Summary

Heron Therapeutics, Inc. filed an 8-K on October 15, 2025, reporting on matters submitted to a vote of security holders and financial statements. The company, formerly known as AP Pharma Inc. and Advanced Polymer Systems Inc., is incorporated in Delaware and headquartered in San Diego, California.

Why It Matters

This filing indicates important corporate actions and financial reporting, which can influence investor decisions and provide insights into the company's operational status.

Risk Assessment

Risk Level: low — This is a routine filing reporting on corporate actions and financial statements, not indicating any immediate material adverse events.

Key Players & Entities

• Heron Therapeutics, Inc. (company) — Registrant
• AP Pharma Inc (company) — Former company name
• Advanced Polymer Systems Inc (company) — Former company name
• Delaware (jurisdiction) — State of incorporation
• October 15, 2025 (date) — Date of report

FAQ

From the Filing

0001193125-25-240253.txt : 20251015 0001193125-25-240253.hdr.sgml : 20251015 20251015160910 ACCESSION NUMBER: 0001193125-25-240253 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20251015 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251015 DATE AS OF CHANGE: 20251015 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HERON THERAPEUTICS, INC. /DE/ CENTRAL INDEX KEY: 0000818033 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 942875566 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33221 FILM NUMBER: 251394921 BUSINESS ADDRESS: STREET 1: 4242 CAMPUS POINT COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582514400 MAIL ADDRESS: STREET 1: 4242 CAMPUS POINT COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: AP PHARMA INC /DE/ DATE OF NAME CHANGE: 20010511 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED POLYMER SYSTEMS INC /DE/ DATE OF NAME CHANGE: 19920703 8-K 1 hrtx-20251015.htm 8-K 8-K 0000818033 false 0000818033 2025-10-15 2025-10-15   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2025 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 100 Regency Forest Drive , Suite 300 , Cary , NC 27518 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code (858) 251-4400 N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share HRTX The Nasdaq  Capital Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐     Item 5.07 Submission of Matters to a Vote of Security Holders. At the Special Stockholders’ Meeting (the “ Special Meeting ”)of Heron Therapeutics, Inc. (the “ Company ”) held on October 13, 2025, the Company’s stockholders voted on two proposals, including: (1) to approve, pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company’s common stock, par value $0.01 per share (“ Common Stock ”) in connection with the conversion, at the option of the holder, of convertible senior unsecured promissory notes due 2031 held by several non-af